Coherus Sees FY23 Net Product Revenue At Least $275M
Portfolio Pulse from Benzinga Newsdesk
Coherus BioSciences expects its 2023 net product revenue to exceed $275 million, including at least $100 million of CIMERLI® net revenue. The company projects combined R&D and SG&A expenses for 2023 to be in the range of $315 to $335 million. This excludes the Surface Oncology acquisition cost and any potential collaboration upfront payments to Klinge Pharma or milestones payments to Junshi Biosciences.
August 04, 2023 | 12:22 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Coherus BioSciences has provided a positive revenue forecast for 2023, which could potentially boost investor confidence and positively impact the stock price in the short term.
Coherus BioSciences' positive revenue forecast for 2023 indicates strong financial performance and growth potential. This could attract more investors, leading to increased demand for the stock and potentially driving up the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100